
A Guide to Virology for Engineers and Applied Scientists

Epidemiology, Emergency Management, and Optimization



A Guide to Virology 1	or Engineers and	Applied Scientist	s	

A Guide to Virology for Engineers and Applied Scientists

Epidemiology, Emergency Management, and Optimization

Megan M. Reynolds and Louis Theodore



This edition first published 2023 © 2023 John Wiley & Sons, Inc.

All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, except as permitted by law. Advice on how to obtain permission to reuse material from this title is available at http://www.wiley.com/go/permissions.

The right of Megan M. Reynolds and Louis Theodore to be identified as the authors of this work has been asserted in accordance with law.

Registered Office John Wiley & Sons, Inc., 111 River Street, Hoboken, NJ 07030, USA

Editorial Office 111 River Street, Hoboken, NJ 07030, USA

For details of our global editorial offices, customer services, and more information about Wiley products visit us at www.wiley.com.

Wiley also publishes its books in a variety of electronic formats and by print-on-demand. Some content that appears in standard print versions of this book may not be available in other formats.

Trademarks: Wiley and the Wiley logo are trademarks or registered trademarks of John Wiley & Sons, Inc. and/or its affiliates in the United States and other countries and may not be used without written permission. All other trademarks are the property of their respective owners. John Wiley & Sons, Inc. is not associated with any product or vendor mentioned in this book.

Limit of Liability/Disclaimer of Warranty

In view of ongoing research, equipment modifications, changes in governmental regulations, and the constant flow of information relating to the use of experimental reagents, equipment, and devices, the reader is urged to review and evaluate the information provided in the package insert or instructions for each chemical, piece of equipment, reagent, or device for, among other things, any changes in the instructions or indication of usage and for added warnings and precautions. While the publisher and authors have used their best efforts in preparing this work, they make no representations or warranties with respect to the accuracy or completeness of the contents of this work and specifically disclaim all warranties, including without limitation any implied warranties of merchantability or fitness for a particular purpose. No warranty may be created or extended by sales representatives, written sales materials or promotional statements for this work. The fact that an organization, website, or product is referred to in this work as a citation and/or potential source of further information does not mean that the publisher and authors endorse the information or services the organization, website, or product may provide or recommendations it may make. This work is sold with the understanding that the publisher is not engaged in rendering professional services. The advice and strategies contained herein may not be suitable for your situation. You should consult with a specialist where appropriate. Further, readers should be aware that websites listed in this work may have changed or disappeared between when this work was written and when it is read. Neither the publisher nor authors shall be liable for any loss of profit or any other commercial damages, including but not limited to special, incidental, consequential, or other damages.

Library of Congress Cataloging-in-Publication Data applied for: Hardback ISBN: 9781119853138

Cover Design: Wiley

Cover Image: © Yuichiro Chino/Getty Images

Set in 9.5/12.5pt STIXTwoText by Straive, Chennai, India

TO

My father, Dr. Joseph P. Reynolds (MMR)

ANI

My friends and colleagues working in the field of virology (LT)

"When an epidemic of physical disease starts to spread, the community approves and joins in a quarantine of the patients in order to protect the health of the community against the spread of the disease..."

Franklin Delano Roosevelt (1882–1945)

Contents

Preface xvii
About the Authors xix

Part I Introduction to Viruses 1

1	Overview of Molecular Biology 3
	Contributing Author: Sarah Forster
1.1	Cell Basics 4
1.1.1	Cytoplasm 5
1.1.2	Ribosomes 5
1.1.3	Nucleus 6
1.2	Cell Replication 6
1.2.1	Nucleic Acids 6
1.2.2	DNA Replication 7
1.2.3	RNA Structure and Role 9
1.2.4	Protein Synthesis 9
1.3	Cellular Transport 11
1.3.1	Plasma Membrane 11
1.3.2	Cell Signaling 11
1.4	Immune Defense 12
1.4.1	Innate Immunity 12
1.4.2	Adaptive Immunity 13
1.4.2.1	Humoral Immunity 13
1.4.2.2	Cellular Immunity 14
1.5	Applications 14
1.6	Chapter Summary 16
1.7	Problems 16
	References 16

ri	ï	i

2	Basics of Virology 19
2.1	Viral Basics and Terminology 19
2.2	Viral Life Cycle 21
2.2.1	Attachment (Connection) 21
2.2.2	Penetration (Entry) 22
2.2.3	Uncoating 22
2.2.4	Replication 23
2.2.5	Assembly 23
2.2.6	Maturation and Release 23
2.3	Virus Structure and Classification 24
2.3.1	DNA Viruses 25
2.3.2	RNA Viruses 25
2.3.3	Reverse Transcription Viruses (Retroviruses) 27
2.4	Viruses in Context of the Tree of Life 27
2.5	Viral Genetics 28
2.5.1	Antigenic Shift 28
2.5.2	Antigenic Drift 29
2.5.3	Phenotypic Mixing 29
2.5.4	Complementation 29
2.6	Applications 29
2.7	Chapter Summary 31
2.8	Problems 31
	References 32
3	Pandemics, Epidemics, and Outbreaks 33
3.1	Human Viral Diseases 34
3.2	Ebola and Marburg Viruses 35
3.2.1	Symptoms 36
3.2.2	Diagnosis 37
3.2.3	Prevention and Treatment 37
3.3	Human Immunodeficiency Disease (HIV) 38
3.3.1	HIV Symptoms 39
3.3.1.1	Stage 1: Acute Infection 39
3.3.1.2	Stage 2: Chronic HIV Infection (Latent Phase) 39
3.3.1.3	Stage 3: Acquired Immunodeficiency Syndrome (AIDS) 39
3.3.2	Diagnosis 40
3.3.3	HIV Prevention and Treatment 40
3.4	Influenza 41
3.4.1	Influenza Symptoms 41
3.4.2	Influenza Diagnosis 42
3.4.3	Influenza Prevention and Treatment 42

3.5 Coronaviruses 44 3.5.1 Symptoms 45 3.5.1.1 Typical Acute Symptoms 45 3.5.1.2 Post-COVID Conditions 46 3.5.1.3 COVID-19 Multiorgan System Effects (MIS) 46 3.5.2 COVID-19 Diagnosis 47 3.5.3 COVID-19 Prevention and treatment 48 3.6 Current and Emerging Viral Threats 48 3.7 Applications 51 3.8 Chapter Summary 52 3.9 Problems 53 References 53 4 Virus Prevention, Diagnosis, and Treatment 57 4.1 Vaccination Successes and Challenges 58 4.2 Current Vaccine Technology 59 4.2.1 Live-attenuated vaccines 60 4.2.2 Inactivated vaccines 61 4.2.3 Recombinant Subunit Vaccines 61 4.2.4 Viral Vector Vaccines 62 4.2.5 Messenger RNA (mRNA) Vaccines 62 4.3 U.SApproved Vaccines and Requirements 63 4.3.1 Commercially Available Viral Vaccines 63 4.3.2 Vaccination Requirements 63 4.4 Viral Testing and Diagnosis 64 4.4.1 Viral Testing 65 4.4.2 Antibody Testing 66 4.5 Antiviral Treatment Options 66
3.5.1.1 Typical Acute Symptoms 45 3.5.1.2 Post-COVID Conditions 46 3.5.1.3 COVID-19 Multiorgan System Effects (MIS) 46 3.5.2 COVID-19 Diagnosis 47 3.5.3 COVID-19 Prevention and treatment 48 3.6 Current and Emerging Viral Threats 48 3.7 Applications 51 3.8 Chapter Summary 52 3.9 Problems 53 References 53 4 Virus Prevention, Diagnosis, and Treatment 57 4.1 Vaccination Successes and Challenges 58 4.2 Current Vaccine Technology 59 4.2.1 Live-attenuated vaccines 60 4.2.2 Inactivated vaccines 61 4.2.3 Recombinant Subunit Vaccines 61 4.2.4 Viral Vector Vaccines 62 4.2.5 Messenger RNA (mRNA) Vaccines 62 4.3 U.SApproved Vaccines and Requirements 63 4.3.1 Commercially Available Viral Vaccines 63 4.3.2 Vaccination Requirements 63 4.4 Viral Testing and Diagnosis 64 4.4.1 Viral Testing 65 4.4.2 Antibody Testing 66
3.5.1.2 Post-COVID Conditions 46 3.5.1.3 COVID-19 Multiorgan System Effects (MIS) 46 3.5.2 COVID-19 Diagnosis 47 3.5.3 COVID-19 Prevention and treatment 48 3.6 Current and Emerging Viral Threats 48 3.7 Applications 51 3.8 Chapter Summary 52 3.9 Problems 53 References 53 4 Virus Prevention, Diagnosis, and Treatment 57 4.1 Vaccination Successes and Challenges 58 4.2 Current Vaccine Technology 59 4.2.1 Live-attenuated vaccines 60 4.2.2 Inactivated vaccines 61 4.2.3 Recombinant Subunit Vaccines 61 4.2.4 Viral Vector Vaccines 62 4.2.5 Messenger RNA (mRNA) Vaccines 62 4.3 U.SApproved Vaccines and Requirements 63 4.3.1 Commercially Available Viral Vaccines 63 4.3.2 Vaccination Requirements 63 4.4 Viral Testing and Diagnosis 64 4.4.1 Viral Testing 65 4.4.2 Antibody Testing 66
3.5.1.3 COVID-19 Multiorgan System Effects (MIS) 46 3.5.2 COVID-19 Diagnosis 47 3.5.3 COVID-19 Prevention and treatment 48 3.6 Current and Emerging Viral Threats 48 3.7 Applications 51 3.8 Chapter Summary 52 3.9 Problems 53 References 53 4 Virus Prevention, Diagnosis, and Treatment 57 4.1 Vaccination Successes and Challenges 58 4.2 Current Vaccine Technology 59 4.2.1 Live-attenuated vaccines 60 4.2.2 Inactivated vaccines 61 4.2.3 Recombinant Subunit Vaccines 61 4.2.4 Viral Vector Vaccines 62 4.2.5 Messenger RNA (mRNA) Vaccines 62 4.3 U.SApproved Vaccines and Requirements 63 4.3.1 Commercially Available Viral Vaccines 63 4.3.2 Vaccination Requirements 63 4.4.4 Viral Testing and Diagnosis 64 4.4.1 Viral Testing 65 4.4.2 Antibody Testing 66
3.5.2 COVID-19 Diagnosis 47 3.5.3 COVID-19 Prevention and treatment 48 3.6 Current and Emerging Viral Threats 48 3.7 Applications 51 3.8 Chapter Summary 52 3.9 Problems 53 References 53 4 Virus Prevention, Diagnosis, and Treatment 57 4.1 Vaccination Successes and Challenges 58 4.2 Current Vaccine Technology 59 4.2.1 Live-attenuated vaccines 60 4.2.2 Inactivated vaccines 61 4.2.3 Recombinant Subunit Vaccines 61 4.2.4 Viral Vector Vaccines 62 4.2.5 Messenger RNA (mRNA) Vaccines 62 4.3 U.SApproved Vaccines and Requirements 63 4.3.1 Commercially Available Viral Vaccines 63 4.3.2 Vaccination Requirements 63 4.4 Viral Testing and Diagnosis 64 4.4.1 Viral Testing 65 4.4.2 Antibody Testing 66
3.5.3 COVID-19 Prevention and treatment 48 3.6 Current and Emerging Viral Threats 48 3.7 Applications 51 3.8 Chapter Summary 52 3.9 Problems 53 References 53 4 Virus Prevention, Diagnosis, and Treatment 57 4.1 Vaccination Successes and Challenges 58 4.2 Current Vaccine Technology 59 4.2.1 Live-attenuated vaccines 60 4.2.2 Inactivated vaccines 61 4.2.3 Recombinant Subunit Vaccines 61 4.2.4 Viral Vector Vaccines 62 4.2.5 Messenger RNA (mRNA) Vaccines 62 4.3 U.SApproved Vaccines and Requirements 63 4.3.1 Commercially Available Viral Vaccines 63 4.3.2 Vaccination Requirements 63 4.4.4 Viral Testing and Diagnosis 64 4.4.1 Viral Testing 65 4.4.2 Antibody Testing 66
3.6 Current and Emerging Viral Threats 48 3.7 Applications 51 3.8 Chapter Summary 52 3.9 Problems 53 References 53 4 Virus Prevention, Diagnosis, and Treatment 57 4.1 Vaccination Successes and Challenges 58 4.2 Current Vaccine Technology 59 4.2.1 Live-attenuated vaccines 60 4.2.2 Inactivated vaccines 61 4.2.3 Recombinant Subunit Vaccines 61 4.2.4 Viral Vector Vaccines 62 4.2.5 Messenger RNA (mRNA) Vaccines 62 4.3 U.SApproved Vaccines and Requirements 63 4.3.1 Commercially Available Viral Vaccines 63 4.3.2 Vaccination Requirements 63 4.4.4 Viral Testing and Diagnosis 64 4.4.1 Viral Testing 65 4.4.2 Antibody Testing 66
3.7 Applications 51 3.8 Chapter Summary 52 3.9 Problems 53 References 53 4 Virus Prevention, Diagnosis, and Treatment 57 4.1 Vaccination Successes and Challenges 58 4.2 Current Vaccine Technology 59 4.2.1 Live-attenuated vaccines 60 4.2.2 Inactivated vaccines 61 4.2.3 Recombinant Subunit Vaccines 61 4.2.4 Viral Vector Vaccines 62 4.2.5 Messenger RNA (mRNA) Vaccines 62 4.3 U.SApproved Vaccines and Requirements 63 4.3.1 Commercially Available Viral Vaccines 63 4.3.2 Vaccination Requirements 63 4.4.4 Viral Testing and Diagnosis 64 4.4.1 Viral Testing 65 4.4.2 Antibody Testing 66
3.8 Chapter Summary 52 3.9 Problems 53 References 53 4 Virus Prevention, Diagnosis, and Treatment 57 4.1 Vaccination Successes and Challenges 58 4.2 Current Vaccine Technology 59 4.2.1 Live-attenuated vaccines 60 4.2.2 Inactivated vaccines 61 4.2.3 Recombinant Subunit Vaccines 61 4.2.4 Viral Vector Vaccines 62 4.2.5 Messenger RNA (mRNA) Vaccines 62 4.3 U.SApproved Vaccines and Requirements 63 4.3.1 Commercially Available Viral Vaccines 63 4.3.2 Vaccination Requirements 63 4.4 Viral Testing and Diagnosis 64 4.4.1 Viral Testing 65 4.4.2 Antibody Testing 66
3.9 Problems 53 References 53 4 Virus Prevention, Diagnosis, and Treatment 57 4.1 Vaccination Successes and Challenges 58 4.2 Current Vaccine Technology 59 4.2.1 Live-attenuated vaccines 60 4.2.2 Inactivated vaccines 61 4.2.3 Recombinant Subunit Vaccines 61 4.2.4 Viral Vector Vaccines 62 4.2.5 Messenger RNA (mRNA) Vaccines 62 4.3 U.SApproved Vaccines and Requirements 63 4.3.1 Commercially Available Viral Vaccines 63 4.3.2 Vaccination Requirements 63 4.4 Viral Testing and Diagnosis 64 4.4.1 Viral Testing 65 4.4.2 Antibody Testing 66
A Virus Prevention, Diagnosis, and Treatment 57 4.1 Vaccination Successes and Challenges 58 4.2 Current Vaccine Technology 59 4.2.1 Live-attenuated vaccines 60 4.2.2 Inactivated vaccines 61 4.2.3 Recombinant Subunit Vaccines 61 4.2.4 Viral Vector Vaccines 62 4.2.5 Messenger RNA (mRNA) Vaccines 62 4.3 U.SApproved Vaccines and Requirements 63 4.3.1 Commercially Available Viral Vaccines 63 4.3.2 Vaccination Requirements 63 4.4 Viral Testing and Diagnosis 64 4.4.1 Viral Testing 65 4.4.2 Antibody Testing 66
4 Virus Prevention, Diagnosis, and Treatment 57 4.1 Vaccination Successes and Challenges 58 4.2 Current Vaccine Technology 59 4.2.1 Live-attenuated vaccines 60 4.2.2 Inactivated vaccines 61 4.2.3 Recombinant Subunit Vaccines 61 4.2.4 Viral Vector Vaccines 62 4.2.5 Messenger RNA (mRNA) Vaccines 62 4.3 U.SApproved Vaccines and Requirements 63 4.3.1 Commercially Available Viral Vaccines 63 4.3.2 Vaccination Requirements 63 4.4 Viral Testing and Diagnosis 64 4.4.1 Viral Testing 65 4.4.2 Antibody Testing 66
4.1 Vaccination Successes and Challenges 58 4.2 Current Vaccine Technology 59 4.2.1 Live-attenuated vaccines 60 4.2.2 Inactivated vaccines 61 4.2.3 Recombinant Subunit Vaccines 61 4.2.4 Viral Vector Vaccines 62 4.2.5 Messenger RNA (mRNA) Vaccines 62 4.3 U.SApproved Vaccines and Requirements 63 4.3.1 Commercially Available Viral Vaccines 63 4.3.2 Vaccination Requirements 63 4.4 Viral Testing and Diagnosis 64 4.4.1 Viral Testing 65 4.4.2 Antibody Testing 66
4.1 Vaccination Successes and Challenges 58 4.2 Current Vaccine Technology 59 4.2.1 Live-attenuated vaccines 60 4.2.2 Inactivated vaccines 61 4.2.3 Recombinant Subunit Vaccines 61 4.2.4 Viral Vector Vaccines 62 4.2.5 Messenger RNA (mRNA) Vaccines 62 4.3 U.SApproved Vaccines and Requirements 63 4.3.1 Commercially Available Viral Vaccines 63 4.3.2 Vaccination Requirements 63 4.4 Viral Testing and Diagnosis 64 4.4.1 Viral Testing 65 4.4.2 Antibody Testing 66
4.2 Current Vaccine Technology 59 4.2.1 Live-attenuated vaccines 60 4.2.2 Inactivated vaccines 61 4.2.3 Recombinant Subunit Vaccines 61 4.2.4 Viral Vector Vaccines 62 4.2.5 Messenger RNA (mRNA) Vaccines 62 4.3 U.SApproved Vaccines and Requirements 63 4.3.1 Commercially Available Viral Vaccines 63 4.3.2 Vaccination Requirements 63 4.4 Viral Testing and Diagnosis 64 4.4.1 Viral Testing 65 4.4.2 Antibody Testing 66
4.2.1 Live-attenuated vaccines 60 4.2.2 Inactivated vaccines 61 4.2.3 Recombinant Subunit Vaccines 61 4.2.4 Viral Vector Vaccines 62 4.2.5 Messenger RNA (mRNA) Vaccines 62 4.3 U.SApproved Vaccines and Requirements 63 4.3.1 Commercially Available Viral Vaccines 63 4.3.2 Vaccination Requirements 63 4.4 Viral Testing and Diagnosis 64 4.4.1 Viral Testing 65 4.4.2 Antibody Testing 66
 4.2.2 Inactivated vaccines 61 4.2.3 Recombinant Subunit Vaccines 61 4.2.4 Viral Vector Vaccines 62 4.2.5 Messenger RNA (mRNA) Vaccines 62 4.3 U.SApproved Vaccines and Requirements 63 4.3.1 Commercially Available Viral Vaccines 63 4.3.2 Vaccination Requirements 63 4.4 Viral Testing and Diagnosis 64 4.4.1 Viral Testing 65 4.4.2 Antibody Testing 66
 4.2.3 Recombinant Subunit Vaccines 61 4.2.4 Viral Vector Vaccines 62 4.2.5 Messenger RNA (mRNA) Vaccines 62 4.3 U.SApproved Vaccines and Requirements 63 4.3.1 Commercially Available Viral Vaccines 63 4.3.2 Vaccination Requirements 63 4.4 Viral Testing and Diagnosis 64 4.4.1 Viral Testing 65 4.4.2 Antibody Testing 66
 4.2.4 Viral Vector Vaccines 62 4.2.5 Messenger RNA (mRNA) Vaccines 62 4.3 U.SApproved Vaccines and Requirements 63 4.3.1 Commercially Available Viral Vaccines 63 4.3.2 Vaccination Requirements 63 4.4 Viral Testing and Diagnosis 64 4.4.1 Viral Testing 65 4.4.2 Antibody Testing 66
 4.2.5 Messenger RNA (mRNA) Vaccines 62 4.3 U.SApproved Vaccines and Requirements 63 4.3.1 Commercially Available Viral Vaccines 63 4.3.2 Vaccination Requirements 63 4.4 Viral Testing and Diagnosis 64 4.4.1 Viral Testing 65 4.4.2 Antibody Testing 66
 4.3 U.SApproved Vaccines and Requirements 63 4.3.1 Commercially Available Viral Vaccines 63 4.3.2 Vaccination Requirements 63 4.4 Viral Testing and Diagnosis 64 4.4.1 Viral Testing 65 4.4.2 Antibody Testing 66
 4.3.1 Commercially Available Viral Vaccines 63 4.3.2 Vaccination Requirements 63 4.4 Viral Testing and Diagnosis 64 4.4.1 Viral Testing 65 4.4.2 Antibody Testing 66
 4.3.2 Vaccination Requirements 63 4.4 Viral Testing and Diagnosis 64 4.4.1 Viral Testing 65 4.4.2 Antibody Testing 66
 4.4 Viral Testing and Diagnosis 64 4.4.1 Viral Testing 65 4.4.2 Antibody Testing 66
4.4.1 Viral Testing 654.4.2 Antibody Testing 66
4.4.2 Antibody Testing 66
· ·
4.5.1 HIV 67
4.5.1.1 Nucleoside Reverse Transcriptase Inhibitors (NRTIs) 67
4.5.1.2 Non-nucleoside Reverse Transcriptase Inhibitors (NNRTIs) 67
4.5.1.3 Protease Inhibitors (PIs) 67
4.5.1.4 Fusion Inhibitors (FIs) 67
4.5.1.5 Integrase Strand Transfer Inhibitors (INSTIs) 67
4.5.1.6 CCR5 Antagonists 67
4.5.1.7 Attachment Inhibitors 68
4.5.1.8 Post-Attachment Inhibitors 68
4.5.1.9 Pharmacokinetic Enhancers 68
4.5.2 Influenza 68
4.5.3 Hepatitis C virus (HCV) 68

x	Contents	
	4.5.4	Other Treatment Options 69
	4.6	Applications 70
	4.7	Chapter Summary 71
	4.8	Problems 72
		References 72
	5	Safety Protocols and Personal Protection Equipment 75
		Contributing Author: Emma Parente
	5.1	Regulations and Oversight of Safety Protocols 76
	5.2	Protective and Safety Systems 76
	5.2.1	Personal Protective Devices and Practices 76
	5.2.2	Antimicrobial Suppression And Eradication 77
	5.3	Disinfection Categories and Procedures 78
	5.4	Occupational Health and Safety Administration Hazmat
		Regulations 79
	5.4.1	HAZMAT Level A Protection 80
	5.4.2	HAZMAT Level B Protection 81
	5.4.3	Level C Protection 82
	5.4.4	Level D Protection 83
	5.5	Bio Level Safety and Security 83
	5.6	COVID-Related Safety Precautions 84
	5.6.1	Personal Protective Equipment 84
	5.6.2	Transmission Control 85
	5.7	Applications 85
	5.8	Summary 87
	5.9	Problems 87
		References 88

Epidemiology and Virus Transmission 91 6 Overview of Epidemiology 92 6.1 6.2 Government Agencies' Contributions to Public Health 94 The Role of the Centers for Disease Control and Prevention (CDC) 94 6.2.1 6.2.2 The World Health Organization (WHO): Successes and Challenges 95 6.3 Epidemiologic Study Design 96 Outbreak Case Example 98 6.3.1 6.3.2 Clinical Trials 99 6.4 Virus Transmission 100 6.4.1 Modes of Transmission 101 Applications 102 6.5 Chapter Summary 104 6.6 6.7 Problems 105

References 105

Part II Practical and Technical Considerations 109

7	Engineering Principles and Fundamentals 111
	Contributing Author: Vishal Bhatty
7.1	History of Engineering 112
7.2	Problem Solving: The Engineering Approach 113
7.2.1	Problem-Solving Methodology 114
7.2.2	Engineering and Scientific Sources 115
7.3	Units and Conversion Constants 115
7.3.1	The Metric System 115
7.3.2	The SI System 117
7.4	Dimensional Analysis 117
7.5	Process Variables 119
7.6	The Conservation Laws 121
7.7	Thermodynamics and Kinetics 125
7.8	Applications 126
7.9	Chapter Summary 130
7.10	Problems 130
	References 131
8	Legal and Regulatory Considerations 133
8.1	The Regulatory System 134
8.1.1	Laws, Regulations, Plans and policy: The Differences 135
8.1.2	Policies and Plans 137
8.2	The Role of Individual States 138
8.3	Key Government Agencies 140
8.3.1	Environmental Protection Agency (EPA) 140
8.3.2	Centers for Disease Control and Prevention (CDC) 141
8.3.3	Food and Drug Administration (FDA) 141
8.3.4	Occupational Health and Safety Administration (OSHA) 141
8.3.5	Legal Considerations during a Public Health Crisis 142
8.4	Public Health Emergency Declarations 143
8.5	Key Environmental Acts 145
8.6	The Clean Air Act 145
8.7	Regulation of Toxic Substances 147
8.7.1	Toxic Water Pollutants: Control and Classification 150
8.7.2	Drinking Water 150
8.7.3	Surface Water Treatment Rules (SWTR) 151
8.8	Regulations Governing Infectious Diseases 153
8.8.1	Vaccination Laws 155
8.8.2	State Healthcare Worker and Patient Vaccination Laws 155
8.8.3	State-Mandated Childhood Vaccinations 155

xii	Contents		
-----	----------	--	--

8.9	Applications 155
8.10	Chapter Summary 159
8.11	Problems 159
	References 160
9	Emergency Planning and Response 163
9.1	The Importance of Emergency Planning and Response 164
9.2	Planning for Emergencies 166
9.2.1	Preparedness Training 166
9.3	Plan Implementation 167
9.3.1	Notification of Public and Regulatory Officials 168
9.4	EP&R for Epidemics and Pandemics 169
9.4.1	Federal Public Health and Medical Emergency Preparedness 170
9.4.2	Emergency Operations Center 170
9.4.3	Disease Containment 172
9.4.4	Public Notification of Pandemic Quarantines and Lockdowns 173
9.4.5	The National Strategy for Pandemic Influenza (NSPI) 173
9.5	EP&R for Industrial Accidents 174
9.5.1	Emergency Planning and Community Right-to-Know Act
	(EPCRA) 175
9.5.2	The Planning Committee 177
9.6	EP&R for Natural Disasters 179
9.7	Current and Future Trends 181
9.8	Applications 181
9.9	Chapter Summary 184
9.10	Problems 184
	References 185
10	Ethical Considerations within Virology 189
	Contributing Author: Paul DiGaetano, Jr.
10.1	Core Ethics Principles 190
10.2	Important Tenets of Ethical Research 191
	important renets of Etinear Research 191
10.2.1	Conducting Research During a Health Crisis 192
10.2.1 10.2.2	-
	Conducting Research During a Health Crisis 192
10.2.2	Conducting Research During a Health Crisis 192 Scientific Cooperation During a Health Crisis 192
10.2.2 10.2.3	Conducting Research During a Health Crisis 192 Scientific Cooperation During a Health Crisis 192 Fair and Ethical Study Design and Implementation 193
10.2.2 10.2.3 10.3	Conducting Research During a Health Crisis 192 Scientific Cooperation During a Health Crisis 192 Fair and Ethical Study Design and Implementation 193 Ethical Dilemmas in Public Health 193
10.2.2 10.2.3 10.3 10.3.1	Conducting Research During a Health Crisis 192 Scientific Cooperation During a Health Crisis 192 Fair and Ethical Study Design and Implementation 193 Ethical Dilemmas in Public Health 193 Public Health Surveillance 193
10.2.2 10.2.3 10.3 10.3.1 10.3.2	Conducting Research During a Health Crisis 192 Scientific Cooperation During a Health Crisis 192 Fair and Ethical Study Design and Implementation 193 Ethical Dilemmas in Public Health 193 Public Health Surveillance 193 Ethical Evaluation of Nonpharmaceutical Interventions 195

10.5	Applications 201
10.6	Chapter Summary 202
10.7	Problems 203
	References 203
11	Health and Hazard Risk Assessment 205
11.1	Introduction to Risk Assessment 207
11.2	The Health Risk Assessment Process 209
11.3	Dose–Response Assessment 211
11.4	The Hazard Risk Assessment Process 213
11.5	Hazard Risk Versus Health Risk 214
11.5.1	Health Risk Assessment (HRA) Example 215
11.5.2	Hazard Risk Assessment (HRZA) Example 215
11.6	COVID-19 Pandemic Hazard Risk 216
11.7	The Uncertainty Factor 217
11.8	Applications 218
11.9	Chapter Summary 220
11.10	Problems 220
	References 221
	Part III Engineering Considerations 223
12	-
12	Introduction to Mathematical Methods 225
	Introduction to Mathematical Methods 225 Contributing Author: Julian Theodore
12.1	Introduction to Mathematical Methods 225 Contributing Author: Julian Theodore Differentiation 226
12.1 12.2	Introduction to Mathematical Methods 225 Contributing Author: Julian Theodore Differentiation 226 Integration 228
12.1 12.2 12.2.1	Introduction to Mathematical Methods 225 Contributing Author: Julian Theodore Differentiation 226 Integration 228 The Trapezoidal Rule 228
12.1 12.2 12.2.1 12.2.2	Introduction to Mathematical Methods 225 Contributing Author: Julian Theodore Differentiation 226 Integration 228 The Trapezoidal Rule 228 Simpson's Rule 229
12.1 12.2 12.2.1 12.2.2 12.3	Introduction to Mathematical Methods 225 Contributing Author: Julian Theodore Differentiation 226 Integration 228 The Trapezoidal Rule 228 Simpson's Rule 229 Simultaneous Linear Algebraic Equations 230
12.1 12.2 12.2.1 12.2.2 12.3 12.3.1	Introduction to Mathematical Methods 225 Contributing Author: Julian Theodore Differentiation 226 Integration 228 The Trapezoidal Rule 228 Simpson's Rule 229 Simultaneous Linear Algebraic Equations 230 Gauss-Jordan Reduction 231
12.1 12.2 12.2.1 12.2.2 12.3 12.3.1 12.3.2	Introduction to Mathematical Methods 225 Contributing Author: Julian Theodore Differentiation 226 Integration 228 The Trapezoidal Rule 228 Simpson's Rule 229 Simultaneous Linear Algebraic Equations 230 Gauss–Jordan Reduction 231 Gauss Elimination 232
12.1 12.2 12.2.1 12.2.2 12.3 12.3.1 12.3.2 12.3.3	Introduction to Mathematical Methods 225 Contributing Author: Julian Theodore Differentiation 226 Integration 228 The Trapezoidal Rule 228 Simpson's Rule 229 Simultaneous Linear Algebraic Equations 230 Gauss–Jordan Reduction 231 Gauss Elimination 232 Gauss–Seidel Approach 232
12.1 12.2 12.2.1 12.2.2 12.3 12.3.1 12.3.2 12.3.3 12.4	Introduction to Mathematical Methods 225 Contributing Author: Julian Theodore Differentiation 226 Integration 228 The Trapezoidal Rule 228 Simpson's Rule 229 Simultaneous Linear Algebraic Equations 230 Gauss-Jordan Reduction 231 Gauss Elimination 232 Gauss-Seidel Approach 232 Nonlinear Algebraic Equations 233
12.1 12.2 12.2.1 12.2.2 12.3 12.3.1 12.3.2 12.3.3 12.4 12.5	Introduction to Mathematical Methods 225 Contributing Author: Julian Theodore Differentiation 226 Integration 228 The Trapezoidal Rule 228 Simpson's Rule 229 Simultaneous Linear Algebraic Equations 230 Gauss–Jordan Reduction 231 Gauss Elimination 232 Gauss–Seidel Approach 232 Nonlinear Algebraic Equations 233 Ordinary Differential Equations 234
12.1 12.2 12.2.1 12.2.2 12.3 12.3.1 12.3.2 12.3.3 12.4 12.5 12.6	Introduction to Mathematical Methods 225 Contributing Author: Julian Theodore Differentiation 226 Integration 228 The Trapezoidal Rule 228 Simpson's Rule 229 Simultaneous Linear Algebraic Equations 230 Gauss-Jordan Reduction 231 Gauss Elimination 232 Gauss-Seidel Approach 232 Nonlinear Algebraic Equations 233 Ordinary Differential Equations 234 Partial Differential Equations 237
12.1 12.2 12.2.1 12.2.2 12.3 12.3.1 12.3.2 12.3.3 12.4 12.5 12.6 12.7	Introduction to Mathematical Methods 225 Contributing Author: Julian Theodore Differentiation 226 Integration 228 The Trapezoidal Rule 228 Simpson's Rule 229 Simultaneous Linear Algebraic Equations 230 Gauss-Jordan Reduction 231 Gauss Elimination 232 Gauss-Seidel Approach 232 Nonlinear Algebraic Equations 233 Ordinary Differential Equations 234 Partial Differential Equations 237 Applications 237
12.1 12.2 12.2.1 12.2.2 12.3 12.3.1 12.3.2 12.3.3 12.4 12.5 12.6	Introduction to Mathematical Methods 225 Contributing Author: Julian Theodore Differentiation 226 Integration 228 The Trapezoidal Rule 228 Simpson's Rule 229 Simultaneous Linear Algebraic Equations 230 Gauss-Jordan Reduction 231 Gauss Elimination 232 Gauss-Seidel Approach 232 Nonlinear Algebraic Equations 233 Ordinary Differential Equations 234 Partial Differential Equations 237

13	Probability and Statistical Principles 243				
13.1	Probability Definitions and Interpretations 244				
13.2	Introduction to Probability Distributions 246				
13.3	Discrete Probability Distributions 247				
13.3.1	The Binomial Distribution 248				
13.3.2	Multinomial Distribution 248				
13.3.3	Hypergeometric Distribution 249				
13.3.4	Poisson Distribution 250				
13.4	Continuous Probability Distributions 250				
13.4.1	Measures of Central Tendency and Scatter 251				
13.4.2	The Normal Distribution 252				
13.4.3	The Lognormal Distribution 256				
13.4.4	The Exponential Distribution 257				
13.4.5	The Weibull Distribution 258				
13.5	Contemporary Statistics 259				
13.5.1	Confidence Intervals for Means 260				
13.5.2	Confidence Intervals for Proportions 260				
13.5.3	Hypothesis Testing 261				
13.5.4	Hypothesis Test for Means and Proportions 261				
13.5.5	The F Distribution 262				
13.5.6	Analysis of Variance (ANOVA) 262				
13.5.7	Nonparametric Tests 264				
13.6	Applications 264				
13.7	Chapter Summary 268				
13.8	Problems 268				
	References 269				
14	Linear Regression 271				
14.1	Rectangular Coordinates 272				
14.2	Logarithmic Coordinates 273				
14.3	Methods of Plotting Data 275				
14.4	Scatter Diagrams 275				
14.5	Curve Fitting 278				
14.6	Method of Least Squares 280				
14.7	Applications 284				
14.8	Chapter Summary 287				
14.9	Problems 288				
	References 288				
15	Ventilation 289				
15.1	Introduction to Industrial Ventilation Systems 290				
15.2	Components of Ventilation Systems 291				
	-				

15.3	Fans, Valves and Fittings, and Ductwork 293	
15.3.1	Fans 293	
15.3.2	Valves and Fittings 295	
15.4	Selecting Ventilation Systems 296	
15.5	Key Process Equations 298	
15.5.1	Regarding Friction Losses 299	
15.6	Ventilation Models 300	
15.7	Model Limitations 302	
15.8	Infection Control Implications 303	
15.9	Applications 305	
15.10	Chapter Summary 309	
15.11	Problems 310	
	References 310	
16	Pandemic Health Data Modeling 313	
16.1	COVID-19: A Rude Awakening 315	
16.2	Earlier Work 316	
16.3	Planning for Pandemics 318	
16.4	Generating Mathematical Models 319	
16.5	Pandemic Health Data Models 324	
16.6	In Review 329	
16.7	Applications 331	
16.8	Chapter Summary 338	
16.9	Problems 338	
	References 339	
17	Optimization Procedures 341	
17.1	The History of Optimization 342	
17.2	The Scope of Optimization 344	
17.3	Conventional Optimization Procedures 346	
17.4	Analytical Fomulation of the Optimum 347	
17.5		50
17.6	Applied Concepts in Linear Programming 351	
17.7	Applications 355	
17.8	Chapter Summary 357	
17.9	Problems 358	
	References 359	

Index 361

Preface

As its title implies, this book offers a guide to virology which provides information on viruses from an engineer's and applied scientist's perspective. Concise and easy to use, this guide brings together a wealth of general information on viruses in one compact book. It additionally offers practical and technical information plus calculation details.

The guide has been written not only for students but also for those in technical roles, such as engineers and applied scientists who work in public health, pharmaceuticals, or other health-related fields. It is a tool that may be used whenever and wherever information about viruses is likely to be sought.

In the wake of the COVID-19 pandemic, it has become evident that knowledge of virology is no longer critical only to doctors or epidemiologists; there is an urgent need for cooperation among varied disciplines to address the current pandemic and prepare for the next one. The authors feel that no one source currently covers all of the information on viruses in the manner presented in this book. It is hoped that this book will serve to fill the growing need for concise and digestible information – both academically and professionally – in these fields.

The guide is divided into three parts. Part I provides an overview of the science of viruses, including what they are, how they work, and how illnesses can be prevented and treated. Parts II and III provide information on practical/technical considerations and on calculation details, respectively. In addition, a number of illustrative examples are included for each chapter.

Reasonable care has been taken to ensure the accuracy of the information contained in this book. However, the authors and the publisher cannot be held responsible for erroneous omissions in the information presented or for any consequences arising from the use of the information published in the book. Accordingly, reference to original sources is encouraged. Reporting of any errors or omissions is solicited in order to ensure that appropriate changes may be made in future editions.

xviii | Preface

The authors wish to thank the following individuals for their important contributions to the work: Marybeth R. Radics, Mary K. Theodore, Ann Marie Flynn, and Matthew C. Ogwu.

Finally, the authors also wish to acknowledge the contributing authors: Sarah Forster (Overview of Molecular Biology), Emma Parente (Safety Protocols and Personal Protection Equipment), Vishal Bhatty (Engineering Principles and Fundamentals), Paul DiGaetano, Jr. (Ethical Considerations in Virology), and Julian Theodore (Introduction to Mathematical Methods).

August 2022

Megan M. Reynolds Merano, Italy Louis Theodore East Williston, NY

About the Authors

Megan M. Reynolds, BS, MS, MBA, is a freelance medical writer and editor with a particular focus on infectious diseases. With degrees in chemical engineering, international business, and medicine, she worked in the pharmaceutical field in various capacities for more than a dozen years in both the United States and Europe. Her experience encompasses manufacturing, sales, and marketing from managing production scale-up for the launch of new drug manufacturing lines to spearheading an education initiative for healthcare providers at a large New York public hospital aimed at increasing vaccine utilization. She also studied methods for minimizing bacterial resistance due to the overuse of antibiotics. Previous publications include textbook chapter contributions, a case report on the successful treatment of a patient with a rare, highly resistant infection, as well as a medical narrative on treating patients in severe pain. Her recent research interests have focused on addressing the high rate of hospital-acquired infections leading to sepsis and on reducing vaccine hesitancy towards measles, mumps, and rubella vaccine (MMR). Raised in New York City, Ms. Reynolds is multilingual and has lived and worked in several countries, including Italy, Spain, and Germany, and has studied in the United States, Mexico, and Grenada. She is currently based in northern Italy and enjoys living in the Alps while pursuing her passions in rock climbing, yoga, and skiing.

Born and raised in Hell's Kitchen, Louis Theodore received the degrees of MChE and EngScD from the New York University and a BChE from the Cooper Union. For over 50 years, Dr. Theodore was a chemical engineering professor, as well as graduate program director, researcher, professional innovator, and communicator in the engineering field. He has authored numerous texts and reference books, nearly 200 technical papers, and is section editor to the last four editions of Perry's Chemical Engineers' Handbook. He has served as a consultant to the US EPA, DOE and DOJ, and Theodore Tutorials. Dr. Theodore is a member of Phi Lambda Upsilon, Sigma Xi, Tau Beta Pi, American Chemical Society, American Society of Engineering Education, Royal Hellenic Society, and a fellow of the International

xx | About the Authors

Air & Waste Management Association (AWMA). In addition to providing invited testimony to a Presidential (Ford) Crime Commission Hearing, Dr. Theodore was honored at Madison Square Garden in 2008 for his contributions to basketball and the youth of America. His current technical interests include risk management, desalination, and pandemic modeling.

Part I

Introduction to Viruses

Merriam-Webster defines Introduction as "something that introduces, such as,

- a part of a book or treatise preliminary to the main portion,
- a preliminary treatise or course of study" (Merriam-Webster 2022)

Indeed, that is exactly what this Part I of the book is all about. The chapters contain material that one might view as a prerequisite for the technical considerations and engineering calculations that are addressed in Parts II and III, respectively.

It is no secret that viruses are responsible for a host of diseases that can include something as simple as the so-called "common" cold to those that are more serious and fatal, i.e., COVID-19, West Nile, AIDS, Ebola, etc. The technical community began to realize that viruses, in general, were responsible for a range of diseases at the turn of the 20th century. The variation in disease severity occurs because various viruses attack different tissues and organs. In addition, one of the problems with virus detection has been the extremely small size of many of viruses, i.e., both the SARS-CoV-2 and polio viruses are in the 0.01-0.1-micron size range.

There are six chapters covering these issues in Part I. The chapter numbers and accompanying titles are listed below:

Chapter 1: Overview of Molecular Biology

Chapter 2: Basics of Virology

Chapter 3: Pandemics, Epidemics, and Outbreaks

Chapter 4: Virus Prevention, Diagnosis, and Treatment

Chapter 5: Safety Protocols and Personal Protection Equipment

Chapter 6: Epidemiology and Virus Transmission

A Guide to Virology for Engineers and Applied Scientists: Epidemiology, Emergency Management, and Optimization, First Edition. Megan M. Reynolds and Louis Theodore.
© 2023 John Wiley & Sons, Inc. Published 2023 by John Wiley & Sons, Inc.

1

Overview of Molecular Biology

Contributing Author: Sarah Forster

CHAPTER MENU

Cell Basics, 4
Cell Replication, 6
Cellular Transport, 11
Immune Defense, 12
Applications, 14
Chapter Summary, 16
Problems, 16
References, 16

After much deliberation, the authors have decided to include a preliminary chapter concerned with molecular biology and the immune system. This decision was based on the fact that the book was written for engineers and applied scientists who may not have a background in biology. Why the inclusion? The authors felt that these topics, for those interested, could provide the readers with a better understanding of how cells function under normal circumstances, and thus better comprehend how viruses take over and use these mechanisms against the body.

Biology, as the science of life, involves the general study of living forms. *Molecular* biology, which includes *biophysics* and *biochemistry*, has made fundamental contributions to modern biology. Thus, more information is now available about the structure and function of nucleic acids – the base of DNA and proteins, and the key molecules of all living matter. *Cellular* biology is closely related to molecular biology (the title of this chapter). It primarily deals with the functions of the cell – the basic structural unit of life – which studies its components and their

interactions. The life functions of multicellular organisms are governed by the activities and interactions of their cellular components. The study of organisms includes not only their growth and development but also how they function.

When a virus infects a host, it utilizes the genetic code of the invaded cell to hijack the normal replication process in order to replicate numerous copies of itself. Thus, it is helpful to have some understanding as to how genetic coding works under normal circumstances, in order to fully comprehend the complex mechanism with which the virus commandeers a cell for its own purposes. While viruses are not themselves cellular, they do contain the same basic genetic materials as cells, either DNA or RNA.

This chapter attempts to provide the reader with some of the key terms that have become integral to the study of molecular biology. The chapter also endeavors to offer a framework of normal cell functions critical to the understanding of virology. Chapter 2: Basics of Virology, the next chapter, utilizes this framework to depict how viruses invade and hijack standard cell function. Hopefully, the importance of the definitions and explanations in this earlier section will become clear. In the same vein, those already familiar with molecular biology may wish to skip this chapter in favor of Chapter 2.

1.1 CELL BASICS

This section describes the basic concepts of eukaryotic cells, which compose all multicellular organisms, such as humans, animals, and plants. Alternatively, single-celled microorganisms such as bacteria are referred to as prokaryotes. Different viruses infect different types of cells. As discussed above, Chapter 2 further examines how viruses invade and infect human cells.

Within each eukaryotic cell is a highly complex system of organelles - the tiny cellular structures that perform specific functions within the cell. These structures keep the cell running, much like organs do in the human body. Several key organelles are shown below in Figure 1.1.

(Louten 2016)

The following subsections below highlight a few organelles that play a crucial role during virus invasion leading to infection. These include the cytoplasm, ribosomes, and nucleus.




Figure 1.1 Illustration of organelles within a cell. Source: National Cancer Institute/U.S. Department of Health and Human Services/Public Domain.

1.1.1 CYTOPLASM

The cytoplasm is one of the most important organelles within the cell membrane since it holds the other organelles together in its gel-like composition and allows for numerous processes to occur within the cell through the suspension of organelles and cellular molecules. Cytoplasm also allows for the occurrence of biochemical reactions within the cell, such as the replication of RNA viruses and protein synthesis (Denison 2008). The replication of RNA viruses occurs here in the cytoplasm as a majority of the enzymes used to replicate RNA are virally encoded.

1.1.2 RIBOSOMES

Ribosomes found in the cytosol play an important role in the manufacture of proteins within the cell. These ribosomes are located not only attached to the rough endoplasmic reticulum (rER), but also floating within the cytosol. The ribosomes attached to the endoplasmic reticulum have the ability to create proteins. Once transferred to the lumen, proteins are modified to be utilized by the remaining organelles throughout the cell. This is all possible due to the binding of the ribosomes to the messenger RNA (mRNA) prior to the production of proteins (Louten 2016). Viruses have the ability to overtake the production of these proteins by the ribosomes for their own use.

1.1.3 Nucleus

The nucleus within eukaryotic cells contains organelles necessary for the regulation of cellular activities as well as the structures that contain the cell's DNA and other hereditary information. These structures inside the nucleus are comprised of chromosomes, the nuclear matrix, nucleoli, the nucleoplasm, the outer and inner nuclear membranes as well as the nuclear pores (Louten 2016).

The nucleus also allows for the replication of DNA which is then transcribed into messenger RNA to be used throughout the cell. Because of this, viruses must be able to have access to the cell's nucleus in order to replicate their DNA and attack other cells (Geer and Messersmith 2002).

1.2 **CELL REPLICATION**

Cell replication is a detailed process involving the copying of DNA to make new cells. DNA contains the genetic code that is present in every cell in the human body. DNA and RNA are both made up of nucleic acids, which are described below. They are critical to the process of replication and survival, not only for the cell but also for the invading virus (Denison 2008).


1 2 1 NUCLEIC ACIDS

This subsection will review the structure and function of DNA and RNA, which, as previously mentioned, are both made up of various nucleotides. Nucleotides are the basic building blocks for all living organisms, and are a crucial component in all cells. Nucleotides are comprised of three basic components:

- A five-carbon sugar molecule (deoxyribose for DNA or ribose for RNA)
- · A phosphate group containing phosphorus and oxygen
- A nitrogenous base, a ringed molecule of nitrogen, oxygen, and hydrogen

There are four variations of nitrogenous bases, and together they form the basic building blocks for all living organisms: adenine (A), guanine (G), cytosine (C), and thymine (T). (Note: Uracil (U) replaces thymine in RNA) Together, these four different nucleotides combine to form polynucleotide base pairs. In DNA, adenine

Figure 1.2 DNA polynucleotide base pairs with sugar-phosphate backbone https://medlineplus.gov/genetics/understanding/basics/dna/



always pairs with thymine, while cytosine pairs with guanine. The pairs are bound together by hydrogen bonds. These base pairs form the coding sequences within the DNA double helix, as shown in Figure 1.2. (Seladi-Schulman 2019; NIH 2010).

The double helix of DNA is structured as two complementary polynucleotide strands, with the leading strand running from the 5' to 3' carbon and the lagging strand running from the 3' to 5' carbon, as shown in the middle of Figure 1.3, below. The base pairs are located within the resulting double helix. The code, which is the order of nucleotides, determines which amino acids will be produced, and therefore, which proteins. Each amino acid is encoded by the order of three nucleotides (Geer and Messersmith 2002).

1.2.2 DNA REPLICATION

The cell cycle consists of four stages including gap $1(G_1)$, synthesis (S Phase), gap $2(G_2)$, and mitosis. Within these four stages, each cell has the ability to grow and divide while also replicating its DNA. The process of DNA replication occurs when the cell creates a direct copy of its chromosomes either during synthesis or during the s-phase of the cell cycle.

As depicted in Figure 1.3, the DNA molecule is untwined during replication, and the two DNA strands are separated from one another through the presence of *cellular enzymes* within the cell. *DNA polymerase* is one of the main




Figure 1.3 DNA Replication https://www.genome.gov/genetics-glossary/DNA-Replication

enzymes utilized in DNA replication due to its ability to place the complementary nucleotides of the new DNA strand in the 5' to 3' direction. DNA polymerase also adds in nucleotides based upon the complementary base pair rules as discussed in the previous section and is highly accurate, so there is a very low rate of misplaced nucleotides. This is shown in Figure 1.3. (Geer and Messersmith 2002).

Working alongside DNA polymerase is an enzyme known as *RNA polymerase* that synthesizes RNA. Similar to DNA polymerase, this enzyme uses a DNA template to produce a section of RNA that adds nucleotides in a 5' to 3' direction while also using the complementary base pair rule. RNA polymerase is known to have a lower rate of fidelity as compared to DNA polymerase (Louten 2016). This fact is highly relevant to virus replication, since an RNA virus tends to have more replicating errors—and as a result, more mutations than a DNA virus, as will be discussed in Chapter 2.

Another enzyme involved with DNA replication is known as *primase*, which is an enzyme that allows DNA polymerase to bind to a formerly single strand of DNA. Primase has the ability to form a double-stranded segment that allows for the binding of DNA polymerase through laying a complementary fragment of RNA on top of the single strand of DNA. (Geer and Messersmith 2002).

Because DNA replication is performed in the cell's nucleus, viruses must gain entry before taking advantage of DNA polymerase and other enzymes to replicate their own genomes and divide further (Louten 2016).